Literature DB >> 24421428

Breakthrough Drug Approval Process and Postmarketing ADR Reporting.

Danial E Baker1.   

Abstract

Year:  2013        PMID： 24421428      PMCID： PMC3859287          DOI： 10.1310/hpj4810-796

Source DB:  PubMed          Journal:  Hosp Pharm        ISSN： 0018-5787


× No keyword cloud information.
  3 in total

1.  Breakthrough drug category demands more communication.

Authors:  John Carroll
Journal:  Manag Care       Date:  2013-08

2.  Developing standards for breakthrough therapy designation in oncology.

Authors:  Sandra J Horning; Daniel A Haber; Wendy K D Selig; S Percy Ivy; Samantha A Roberts; Jeff D Allen; Ellen V Sigal; Charles L Sawyers
Journal:  Clin Cancer Res       Date:  2013-05-29       Impact factor: 12.531

3.  The safety risks of innovation: the FDA's Expedited Drug Development Pathway.

Authors:  Thomas J Moore; Curt D Furberg
Journal:  JAMA       Date:  2012-09-05       Impact factor: 56.272
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.